A rapid and direct liquid chromatography–mass spectrometry (LC–MS) method was developed and validated for high-throughput biomonitoring of Per- and Polyfluoroalkyl Substances (PFAS) in human plasma. This approach streamlines the analytical workflow by replacing traditional, labor-intensive solid-phase extraction (SPE) with a simple protein-precipitation step. Twenty-three PFAS (PFBA, PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnA, PFDoA, HFPO-Da, PFMPA, PFMBA, PFBS, PFPeS, PFHpS, PFOS, ADONA, 4: 2 FTS, 6: 2 FTS, 8: 2 FTS, 9Cl-PF3ONS, 11Cl-PF3OUdS, PFEESA) were monitored. Method detection limits (MDLs) and limits of quantification (LOQs) ranged from 0. 01 to 0. 39 ng/mL and from 0. 04 to 1. 2 ng/mL, respectively. Accuracy (bias) and precision (RSD) were below 16% and 10%, respectively, for all PFAS in both intra- and inter-day experiments. Recoveries ranged from 86 to 102%, and matrix effects were estimated as ion suppression below 30% for all analytes. The method was successfully applied to a cohort of 426 Italian citizens who participated on a voluntary basis. Twelve PFAS were detected, with PFOS and PFOA present in 95% of the samples. The mean and median sums of detected PFAS were 7. 3 ng/mL (SD 4. 6) and 6. 2 ng/mL IQR4. 4-9. 2, respectively, with a maximum total concentration of 35 ng/mL. PFOS isomers (linear + branched) contributed the most to the total PFAS burden in plasma, reaching a maximum concentration of 25 ng/mL. Overall, this method proved to be a reliable and efficient tool for large-scale biomonitoring studies and provides an important basis for investigating the long-term health implications of PFAS exposure.
Fornasari et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: